This content is from: Corporate

Pfizer-Allergan reignites US inversion debate

The controversial megamerger has sparked speculation over US tax authorities' next move to clamp down on the structure

To access our in-house intelligence please request a trial here.

Read this article – and more – for a 30 day period.


Are you already an IFLR subscriber? Login here

Instant access to all of our content. Membership Options | 30 Day Trial